Poor data interoperability in Product Development and Manufacturing owing to different computerized design, analysis, and manufacturing software and hardware systems among functions within companies.
Use Ontologies to provide an integrating environment for information repositories to enable semantic annotation, search/retrieval, and knowledge representation between systems throughout the design to manufacture lifecycle, within companies.
Reduce Operational and Delay Costs from Data Management, Discounted Ontology Development Cost
Savings of 24 FTE-mo per product for Operational Costs; Examples: Data search, retrieval, analysis, and documentation for Process Design, Technology Transfer, Manufacturing, Quality Control, Regulatory Submissions, Inspections, and Annual Reports
Savings of 30 days for Delay (arise from interoperability problems that delay the introduction of a new product); Examples: Manual/Slow processes to ensure data traceability, verify data quality, respond to regulatory questions
Savings from NIIMBL leveraged contract for Ontology Development specialist
The move to standardized ontologies eliminates the need for redundant, manual data mapping, capturing an additional $240K in value per product by reallocating 24 months of FTE labor toward high-value innovation instead of administrative data cleanup. Most critically, this standardized framework de-risks our commercial timeline; by mitigating the 10% chance that a critical-path data error could stall a launch, this protects against potential lost sales—a safeguard valued at $300K per product—ensuring that life-saving therapies reach patients without avoidable digital bottlenecks.
Ontology Data Files (done) Hart (2023) BPI Presentation ? Opensource Biomanufacturing Ontology Kulvatunyou (2023) Presentation Webinar (2023)
Login to the NIIMBL member portal to access additional project information, including presentations, progress updates, reports, and more.
Not yet a member? Learn more about which level of NIIMBL membership is right for you and your organization.

NIIMBL
AstraZeneca
Boehringer Ingelheim
Bristol-Myers Squibb
Cytiva
EMD Millipore Corporation
Eli Lilly and Company
Federal Stakeholder: National Institute of Standards and Technology
Genentech, Inc.
GlaxoSmithKline, LLC
Merck Sharp & Dohme LLC
Pfizer, Inc.
Sanofi
Sartorius Stedim